Thema: US8740602052
TAK, US8740602052
don-3565699_1920.jpg - Foto: THN
Takeda stock advances launch strategy after first-half results
Takeda stock remains focused on launches and pipeline progress. The company raised its FY2026 outlook after first-half results.
ad-hoc-news.de, heute 09:25 Uhr
TAK, US8740602052
Takeda stock gains outlook support as launches advance
Takeda stock follows a higher fiscal-year forecast after first-half results. New medicine launches and pipeline progress remain central to the growth plan.
ad-hoc-news.de, 03.11.26 09:24 Uhr
TAK, US8740602052
Takeda stock: FY2026 outlook rises as cash flow guide improves ...
Takeda stock follows stronger first-half results and progress in new medicines. Management will detail its longer-term growth strategy in December.
ad-hoc-news.de, 02.11.26 15:59 Uhr
TAK, US8740602052
Takeda stock: FY2026 outlook rises as pipeline advances
Takeda stock follows an upgraded FY2026 outlook and positive Phase 3 cancer results. Capital Markets Day is set for December 11.
ad-hoc-news.de, 31.10.26 10:22 Uhr
TAK, US8740602052
Takeda stock gets higher FY2026 outlook after first-half ...
Takeda stock enters a new phase after first-half results and an upgraded FY2026 outlook. New medicines are driving the company's growth plan.
ad-hoc-news.de, 30.10.26 09:41 Uhr
TAK, US8740602052
Analyst consensus raises target for Takeda stock to USD ...
Takeda reports fiscal second-quarter results on October 29. Takeda stock costs EUR 18.50 on October 27, 2026, up 2.21 percent versus the Tradegate close.
ad-hoc-news.de, 27.10.26 15:31 Uhr
TAK, US8740602052
Takeda sets October 29 results date for Takeda Pharmaceutical ...
Takeda presents fiscal 2026 second-quarter results on October 29. Fiscal 2026 guidance calls for JPY 4,640.0 billion revenue.
ad-hoc-news.de, 27.10.26 09:27 Uhr
TAK, US8740602052
14 analysts lift Takeda Pharmaceutical stock target to USD ...
